nodes	percent_of_prediction	percent_of_DWPC	metapath
Nedocromil—HSP90AA1—Mycophenolic acid—Mycophenolate mofetil—psoriasis	0.0227	1	CbGdCrCtD
Nedocromil—HSP90AA1—EBV LMP1 signaling—NFKB1—psoriasis	0.00293	0.00853	CbGpPWpGaD
Nedocromil—PTGDR—GPCR ligand binding—CCL20—psoriasis	0.00293	0.00853	CbGpPWpGaD
Nedocromil—PTGDR—Signaling by GPCR—HCAR2—psoriasis	0.0029	0.00842	CbGpPWpGaD
Nedocromil—HSP90AA1—NOD pathway—NFKBIA—psoriasis	0.00289	0.00841	CbGpPWpGaD
Nedocromil—CYSLTR2—Endothelins—JUN—psoriasis	0.00274	0.00795	CbGpPWpGaD
Nedocromil—CYSLTR2—GPCR downstream signaling—HCAR2—psoriasis	0.0025	0.00728	CbGpPWpGaD
Nedocromil—HSP90AA1—NRF2 pathway—TGFA—psoriasis	0.00235	0.00684	CbGpPWpGaD
Nedocromil—HSP90AA1—Hypoxic and oxygen homeostasis regulation of HIF-1-alpha—TP53—psoriasis	0.00234	0.00681	CbGpPWpGaD
Nedocromil—CYSLTR2—GPCR ligand binding—CCL20—psoriasis	0.0023	0.00669	CbGpPWpGaD
Nedocromil—HSP90AA1—EBV LMP1 signaling—TNF—psoriasis	0.00228	0.00663	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling by GPCR—HCAR2—psoriasis	0.00227	0.00661	CbGpPWpGaD
Nedocromil—HSP90AA1—VEGFR1 specific signals—VEGFA—psoriasis	0.00221	0.00643	CbGpPWpGaD
Nedocromil—HSP90AA1—Glucocorticoid receptor regulatory network—IL4—psoriasis	0.00211	0.00613	CbGpPWpGaD
Nedocromil—CYSLTR1—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.00209	0.00609	CbGpPWpGaD
Nedocromil—HSP90AA1—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	0.00203	0.00589	CbGpPWpGaD
Nedocromil—HSP90AA1—IL2 signaling events mediated by PI3K—NFKB1—psoriasis	0.00201	0.00583	CbGpPWpGaD
Nedocromil—HSP90AA1—EPHA-mediated growth cone collapse—VEGFA—psoriasis	0.00195	0.00566	CbGpPWpGaD
Nedocromil—CYSLTR1—Endothelins—JUN—psoriasis	0.0019	0.00551	CbGpPWpGaD
Nedocromil—HSP90AA1—Integrin-linked kinase signaling—JUN—psoriasis	0.00178	0.00518	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—HCAR2—psoriasis	0.00177	0.00515	CbGpPWpGaD
Nedocromil—HSP90AA1—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	0.00175	0.00509	CbGpPWpGaD
Nedocromil—CYSLTR1—GPCR downstream signaling—HCAR2—psoriasis	0.00174	0.00504	CbGpPWpGaD
Nedocromil—FPR1—GPCR downstream signaling—CCL20—psoriasis	0.00172	0.00499	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—HCAR2—psoriasis	0.00171	0.00498	CbGpPWpGaD
Nedocromil—HSP90AA1—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	0.00169	0.0049	CbGpPWpGaD
Nedocromil—HSP90AA1—Glucocorticoid receptor regulatory network—ICAM1—psoriasis	0.00168	0.00487	CbGpPWpGaD
Nedocromil—PTGDR—GPCR downstream signaling—CCL20—psoriasis	0.00166	0.00482	CbGpPWpGaD
Nedocromil—FPR1—Peptide ligand-binding receptors—CXCL8—psoriasis	0.00161	0.00467	CbGpPWpGaD
Nedocromil—CYSLTR1—GPCR ligand binding—CCL20—psoriasis	0.0016	0.00464	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—HCAR2—psoriasis	0.00158	0.00458	CbGpPWpGaD
Nedocromil—HSP90AA1—Regulation of Androgen receptor activity—JUN—psoriasis	0.00156	0.00454	CbGpPWpGaD
Nedocromil—FPR1—Signaling by GPCR—CCL20—psoriasis	0.00156	0.00453	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—TAGAP—psoriasis	0.00154	0.00447	CbGpPWpGaD
Nedocromil—HSP90AA1—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	0.00153	0.00444	CbGpPWpGaD
Nedocromil—HSP90AA1—Corticotropin-releasing hormone—NFKBIA—psoriasis	0.00152	0.00441	CbGpPWpGaD
Nedocromil—HSP90AA1—TNF alpha Signaling Pathway—NFKBIA—psoriasis	0.00152	0.00441	CbGpPWpGaD
Nedocromil—PTGDR—Signaling by GPCR—CCL20—psoriasis	0.00151	0.00437	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—TAGAP—psoriasis	0.00148	0.00431	CbGpPWpGaD
Nedocromil—HSP90AA1—Regulation of Telomerase—IFNG—psoriasis	0.00148	0.00431	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—KIR2DS1—psoriasis	0.00145	0.00422	CbGpPWpGaD
Nedocromil—FPR1—G alpha (i) signalling events—CXCL8—psoriasis	0.00135	0.00394	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—HCAR2—psoriasis	0.00134	0.0039	CbGpPWpGaD
Nedocromil—HSP90AA1—Aryl Hydrocarbon Receptor—TNF—psoriasis	0.00131	0.00381	CbGpPWpGaD
Nedocromil—HSP90AA1—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	0.00131	0.00381	CbGpPWpGaD
Nedocromil—Sinusitis—Mycophenolate mofetil—psoriasis	0.0013	0.00205	CcSEcCtD
Nedocromil—CYSLTR2—GPCR downstream signaling—CCL20—psoriasis	0.0013	0.00378	CbGpPWpGaD
Nedocromil—Tremor—Mycophenolic acid—psoriasis	0.00129	0.00203	CcSEcCtD
Nedocromil—Bronchitis—Triamcinolone—psoriasis	0.00128	0.00203	CcSEcCtD
Nedocromil—HSP90AA1—Regulation of Telomerase—JUN—psoriasis	0.00128	0.00372	CbGpPWpGaD
Nedocromil—Rhinitis—Cyclosporine—psoriasis	0.00128	0.00202	CcSEcCtD
Nedocromil—Nausea—Methoxsalen—psoriasis	0.00128	0.00202	CcSEcCtD
Nedocromil—HSP90AA1—Glucocorticoid receptor regulatory network—IFNG—psoriasis	0.00128	0.00371	CbGpPWpGaD
Nedocromil—Pharyngitis—Cyclosporine—psoriasis	0.00127	0.002	CcSEcCtD
Nedocromil—CYSLTR2—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—psoriasis	0.00127	0.00368	CbGpPWpGaD
Nedocromil—Conjunctivitis—Prednisolone—psoriasis	0.00126	0.00199	CcSEcCtD
Nedocromil—Hypersensitivity—Acitretin—psoriasis	0.00126	0.00198	CcSEcCtD
Nedocromil—Hypersensitivity—Fluocinolone Acetonide—psoriasis	0.00125	0.00198	CcSEcCtD
Nedocromil—Rhinitis—Mycophenolate mofetil—psoriasis	0.00125	0.00197	CcSEcCtD
Nedocromil—Upper respiratory tract infection—Triamcinolone—psoriasis	0.00124	0.00196	CcSEcCtD
Nedocromil—Pharyngitis—Mycophenolate mofetil—psoriasis	0.00124	0.00195	CcSEcCtD
Nedocromil—HSP90AA1—Regulation of Telomerase—NFKB1—psoriasis	0.00123	0.00358	CbGpPWpGaD
Nedocromil—Visual impairment—Cyclosporine—psoriasis	0.00123	0.00194	CcSEcCtD
Nedocromil—Leukopenia—Mycophenolic acid—psoriasis	0.00123	0.00194	CcSEcCtD
Nedocromil—Asthenia—Acitretin—psoriasis	0.00122	0.00193	CcSEcCtD
Nedocromil—HSP90AA1—LKB1 signaling events—TP53—psoriasis	0.00122	0.00354	CbGpPWpGaD
Nedocromil—Vomiting—Calcitriol—psoriasis	0.00122	0.00192	CcSEcCtD
Nedocromil—Rash—Calcitriol—psoriasis	0.00121	0.00191	CcSEcCtD
Nedocromil—Dermatitis—Calcitriol—psoriasis	0.00121	0.00191	CcSEcCtD
Nedocromil—Headache—Calcitriol—psoriasis	0.0012	0.00189	CcSEcCtD
Nedocromil—Visual impairment—Mycophenolate mofetil—psoriasis	0.0012	0.00189	CcSEcCtD
Nedocromil—Cough—Mycophenolic acid—psoriasis	0.0012	0.00189	CcSEcCtD
Nedocromil—HSP90AA1—Cell Cycle, Mitotic—PTTG1—psoriasis	0.0012	0.00347	CbGpPWpGaD
Nedocromil—Dyspnoea—Hydroxyurea—psoriasis	0.00119	0.00188	CcSEcCtD
Nedocromil—HSP90AA1—Integrins in angiogenesis—VEGFA—psoriasis	0.00119	0.00346	CbGpPWpGaD
Nedocromil—HSP90AA1—Glucocorticoid receptor regulatory network—CXCL8—psoriasis	0.00119	0.00345	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling by GPCR—CCL20—psoriasis	0.00118	0.00343	CbGpPWpGaD
Nedocromil—Dyspepsia—Hydroxyurea—psoriasis	0.00118	0.00186	CcSEcCtD
Nedocromil—Chest pain—Mycophenolic acid—psoriasis	0.00117	0.00185	CcSEcCtD
Nedocromil—Diarrhoea—Acitretin—psoriasis	0.00117	0.00184	CcSEcCtD
Nedocromil—CYSLTR2—Signaling Pathways—TAGAP—psoriasis	0.00116	0.00339	CbGpPWpGaD
Nedocromil—Diarrhoea—Fluocinolone Acetonide—psoriasis	0.00116	0.00184	CcSEcCtD
Nedocromil—Conjunctivitis—Triamcinolone—psoriasis	0.00116	0.00183	CcSEcCtD
Nedocromil—Gastrointestinal disorder—Hydroxyurea—psoriasis	0.00116	0.00182	CcSEcCtD
Nedocromil—Fatigue—Hydroxyurea—psoriasis	0.00115	0.00182	CcSEcCtD
Nedocromil—Pain—Hydroxyurea—psoriasis	0.00114	0.00181	CcSEcCtD
Nedocromil—Dry mouth—Mycophenolic acid—psoriasis	0.00114	0.00181	CcSEcCtD
Nedocromil—Nausea—Calcitriol—psoriasis	0.00114	0.0018	CcSEcCtD
Nedocromil—Dizziness—Acitretin—psoriasis	0.00113	0.00178	CcSEcCtD
Nedocromil—Dizziness—Fluocinolone Acetonide—psoriasis	0.00112	0.00177	CcSEcCtD
Nedocromil—HSP90AA1—Innate Immune System—DDX58—psoriasis	0.00112	0.00326	CbGpPWpGaD
Nedocromil—Visual impairment—Prednisolone—psoriasis	0.00112	0.00177	CcSEcCtD
Nedocromil—HSP90AA1—Signaling events mediated by VEGFR1 and VEGFR2—VEGFA—psoriasis	0.00112	0.00325	CbGpPWpGaD
Nedocromil—HSP90AA1—Glucocorticoid receptor regulatory network—JUN—psoriasis	0.0011	0.0032	CbGpPWpGaD
Nedocromil—HSP90AA1—VEGFA-VEGFR2 Pathway—TYK2—psoriasis	0.0011	0.0032	CbGpPWpGaD
Nedocromil—Dysgeusia—Cyclosporine—psoriasis	0.00109	0.00172	CcSEcCtD
Nedocromil—Vomiting—Acitretin—psoriasis	0.00108	0.00171	CcSEcCtD
Nedocromil—HSP90AA1—Corticotropin-releasing hormone—CXCL8—psoriasis	0.00108	0.00314	CbGpPWpGaD
Nedocromil—Vomiting—Fluocinolone Acetonide—psoriasis	0.00108	0.00171	CcSEcCtD
Nedocromil—FPR1—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	0.00108	0.00313	CbGpPWpGaD
Nedocromil—Rash—Acitretin—psoriasis	0.00107	0.0017	CcSEcCtD
Nedocromil—Dermatitis—Acitretin—psoriasis	0.00107	0.0017	CcSEcCtD
Nedocromil—Rash—Fluocinolone Acetonide—psoriasis	0.00107	0.00169	CcSEcCtD
Nedocromil—Dermatitis—Fluocinolone Acetonide—psoriasis	0.00107	0.00169	CcSEcCtD
Nedocromil—Rhinitis—Triamcinolone—psoriasis	0.00107	0.00169	CcSEcCtD
Nedocromil—HSP90AA1—Cell Cycle—PTTG1—psoriasis	0.00107	0.00311	CbGpPWpGaD
Nedocromil—Headache—Acitretin—psoriasis	0.00107	0.00169	CcSEcCtD
Nedocromil—Headache—Fluocinolone Acetonide—psoriasis	0.00106	0.00168	CcSEcCtD
Nedocromil—HSP90AA1—Glucocorticoid receptor regulatory network—NFKB1—psoriasis	0.00106	0.00308	CbGpPWpGaD
Nedocromil—Dysgeusia—Mycophenolate mofetil—psoriasis	0.00106	0.00168	CcSEcCtD
Nedocromil—Pharyngitis—Triamcinolone—psoriasis	0.00106	0.00167	CcSEcCtD
Nedocromil—Body temperature increased—Hydroxyurea—psoriasis	0.00106	0.00167	CcSEcCtD
Nedocromil—Conjunctivitis—Betamethasone—psoriasis	0.00105	0.00166	CcSEcCtD
Nedocromil—Conjunctivitis—Dexamethasone—psoriasis	0.00105	0.00166	CcSEcCtD
Nedocromil—Tremor—Cyclosporine—psoriasis	0.00104	0.00164	CcSEcCtD
Nedocromil—PTGDR—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	0.00104	0.00302	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling by VEGF—TYK2—psoriasis	0.00104	0.00302	CbGpPWpGaD
Nedocromil—Tremor—Mycophenolate mofetil—psoriasis	0.00102	0.0016	CcSEcCtD
Nedocromil—Nausea—Acitretin—psoriasis	0.00101	0.0016	CcSEcCtD
Nedocromil—Nausea—Fluocinolone Acetonide—psoriasis	0.00101	0.00159	CcSEcCtD
Nedocromil—HSP90AA1—TNF alpha Signaling Pathway—JUN—psoriasis	0.00101	0.00292	CbGpPWpGaD
Nedocromil—Dyspnoea—Mycophenolic acid—psoriasis	0.000999	0.00158	CcSEcCtD
Nedocromil—Leukopenia—Cyclosporine—psoriasis	0.000994	0.00157	CcSEcCtD
Nedocromil—Dyspepsia—Mycophenolic acid—psoriasis	0.000986	0.00156	CcSEcCtD
Nedocromil—Hypersensitivity—Hydroxyurea—psoriasis	0.000986	0.00156	CcSEcCtD
Nedocromil—Leukopenia—Mycophenolate mofetil—psoriasis	0.00097	0.00153	CcSEcCtD
Nedocromil—Cough—Cyclosporine—psoriasis	0.000969	0.00153	CcSEcCtD
Nedocromil—HSP90AA1—Corticotropin-releasing hormone—NFKB1—psoriasis	0.000968	0.00281	CbGpPWpGaD
Nedocromil—HSP90AA1—TNF alpha Signaling Pathway—NFKB1—psoriasis	0.000968	0.00281	CbGpPWpGaD
Nedocromil—Gastrointestinal disorder—Mycophenolic acid—psoriasis	0.000967	0.00153	CcSEcCtD
Nedocromil—Fatigue—Mycophenolic acid—psoriasis	0.000966	0.00153	CcSEcCtD
Nedocromil—Asthenia—Hydroxyurea—psoriasis	0.00096	0.00152	CcSEcCtD
Nedocromil—Pain—Mycophenolic acid—psoriasis	0.000958	0.00151	CcSEcCtD
Nedocromil—Chest pain—Cyclosporine—psoriasis	0.000946	0.00149	CcSEcCtD
Nedocromil—Cough—Mycophenolate mofetil—psoriasis	0.000945	0.00149	CcSEcCtD
Nedocromil—Visual impairment—Dexamethasone—psoriasis	0.000934	0.00147	CcSEcCtD
Nedocromil—Visual impairment—Betamethasone—psoriasis	0.000934	0.00147	CcSEcCtD
Nedocromil—CYSLTR1—Signaling Pathways—HCAR2—psoriasis	0.000931	0.00271	CbGpPWpGaD
Nedocromil—Dry mouth—Cyclosporine—psoriasis	0.000925	0.00146	CcSEcCtD
Nedocromil—Chest pain—Mycophenolate mofetil—psoriasis	0.000922	0.00146	CcSEcCtD
Nedocromil—FPR1—Signaling Pathways—CCL20—psoriasis	0.000921	0.00268	CbGpPWpGaD
Nedocromil—Gastrointestinal pain—Mycophenolic acid—psoriasis	0.000916	0.00145	CcSEcCtD
Nedocromil—Diarrhoea—Hydroxyurea—psoriasis	0.000915	0.00145	CcSEcCtD
Nedocromil—Dysgeusia—Triamcinolone—psoriasis	0.00091	0.00144	CcSEcCtD
Nedocromil—Anaphylactic shock—Cyclosporine—psoriasis	0.000906	0.00143	CcSEcCtD
Nedocromil—Dry mouth—Mycophenolate mofetil—psoriasis	0.000902	0.00142	CcSEcCtD
Nedocromil—CYSLTR1—GPCR downstream signaling—CCL20—psoriasis	0.000902	0.00262	CbGpPWpGaD
Nedocromil—HSP90AA1—Cellular responses to stress—CAT—psoriasis	0.000901	0.00262	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—CCL20—psoriasis	0.000889	0.00258	CbGpPWpGaD
Nedocromil—HSP90AA1—Developmental Biology—CARM1—psoriasis	0.000888	0.00258	CbGpPWpGaD
Nedocromil—Body temperature increased—Mycophenolic acid—psoriasis	0.000886	0.0014	CcSEcCtD
Nedocromil—Abdominal pain—Mycophenolic acid—psoriasis	0.000886	0.0014	CcSEcCtD
Nedocromil—Dizziness—Hydroxyurea—psoriasis	0.000885	0.0014	CcSEcCtD
Nedocromil—Anaphylactic shock—Mycophenolate mofetil—psoriasis	0.000884	0.0014	CcSEcCtD
Nedocromil—CYSLTR1—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—psoriasis	0.000877	0.00255	CbGpPWpGaD
Nedocromil—Eosinophilia—Methotrexate—psoriasis	0.000872	0.00138	CcSEcCtD
Nedocromil—HSP90AA1—EPH-Ephrin signaling—VEGFA—psoriasis	0.000863	0.00251	CbGpPWpGaD
Nedocromil—Vomiting—Hydroxyurea—psoriasis	0.000851	0.00134	CcSEcCtD
Nedocromil—HSP90AA1—Metabolism—NDUFA5—psoriasis	0.00085	0.00247	CbGpPWpGaD
Nedocromil—Rash—Hydroxyurea—psoriasis	0.000844	0.00133	CcSEcCtD
Nedocromil—Dermatitis—Hydroxyurea—psoriasis	0.000843	0.00133	CcSEcCtD
Nedocromil—Headache—Hydroxyurea—psoriasis	0.000838	0.00132	CcSEcCtD
Nedocromil—Anaphylactic shock—Prednisolone—psoriasis	0.000825	0.0013	CcSEcCtD
Nedocromil—FPR1—GPCR ligand binding—CXCL8—psoriasis	0.00082	0.00238	CbGpPWpGaD
Nedocromil—Upper respiratory tract infection—Methotrexate—psoriasis	0.000819	0.00129	CcSEcCtD
Nedocromil—CYSLTR1—Signaling by GPCR—CCL20—psoriasis	0.000819	0.00238	CbGpPWpGaD
Nedocromil—CYSLTR2—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	0.000816	0.00237	CbGpPWpGaD
Nedocromil—Cough—Triamcinolone—psoriasis	0.000811	0.00128	CcSEcCtD
Nedocromil—Dyspnoea—Cyclosporine—psoriasis	0.000808	0.00128	CcSEcCtD
Nedocromil—CYSLTR1—Signaling Pathways—TAGAP—psoriasis	0.000807	0.00235	CbGpPWpGaD
Nedocromil—Anaphylactic shock—Hydrocortisone—psoriasis	0.000806	0.00127	CcSEcCtD
Nedocromil—Asthenia—Mycophenolic acid—psoriasis	0.000804	0.00127	CcSEcCtD
Nedocromil—Dyspepsia—Cyclosporine—psoriasis	0.000798	0.00126	CcSEcCtD
Nedocromil—Nausea—Hydroxyurea—psoriasis	0.000795	0.00125	CcSEcCtD
Nedocromil—PTGDR—GPCR ligand binding—CXCL8—psoriasis	0.000792	0.0023	CbGpPWpGaD
Nedocromil—Pneumonia—Methotrexate—psoriasis	0.00079	0.00125	CcSEcCtD
Nedocromil—Dyspnoea—Mycophenolate mofetil—psoriasis	0.000788	0.00124	CcSEcCtD
Nedocromil—HSP90AA1—Signaling by ERBB2—TYK2—psoriasis	0.000786	0.00228	CbGpPWpGaD
Nedocromil—Gastrointestinal disorder—Cyclosporine—psoriasis	0.000783	0.00124	CcSEcCtD
Nedocromil—Fatigue—Cyclosporine—psoriasis	0.000782	0.00123	CcSEcCtD
Nedocromil—Dyspepsia—Mycophenolate mofetil—psoriasis	0.000778	0.00123	CcSEcCtD
Nedocromil—HSP90AA1—VEGFA-VEGFR2 Pathway—VEGFA—psoriasis	0.000778	0.00226	CbGpPWpGaD
Nedocromil—Pain—Cyclosporine—psoriasis	0.000775	0.00122	CcSEcCtD
Nedocromil—Dry mouth—Triamcinolone—psoriasis	0.000774	0.00122	CcSEcCtD
Nedocromil—HSP90AA1—Innate Immune System—IFIH1—psoriasis	0.000773	0.00225	CbGpPWpGaD
Nedocromil—Diarrhoea—Mycophenolic acid—psoriasis	0.000767	0.00121	CcSEcCtD
Nedocromil—Conjunctivitis—Methotrexate—psoriasis	0.000763	0.00121	CcSEcCtD
Nedocromil—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	0.000763	0.00121	CcSEcCtD
Nedocromil—Anaphylactic shock—Triamcinolone—psoriasis	0.000759	0.0012	CcSEcCtD
Nedocromil—Pain—Mycophenolate mofetil—psoriasis	0.000756	0.00119	CcSEcCtD
Nedocromil—HSP90AA1—TNF alpha Signaling Pathway—TNF—psoriasis	0.000753	0.00219	CbGpPWpGaD
Nedocromil—HSP90AA1—Validated targets of C-MYC transcriptional activation—TP53—psoriasis	0.00075	0.00218	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—ERAP1—psoriasis	0.000743	0.00216	CbGpPWpGaD
Nedocromil—Gastrointestinal pain—Cyclosporine—psoriasis	0.000741	0.00117	CcSEcCtD
Nedocromil—Dizziness—Mycophenolic acid—psoriasis	0.000741	0.00117	CcSEcCtD
Nedocromil—HSP90AA1—Signaling by VEGF—VEGFA—psoriasis	0.000735	0.00214	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—HLA-C—psoriasis	0.000732	0.00213	CbGpPWpGaD
Nedocromil—HSP90AA1—Glucocorticoid receptor regulatory network—TP53—psoriasis	0.000728	0.00211	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—TNFAIP3—psoriasis	0.000723	0.0021	CbGpPWpGaD
Nedocromil—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	0.000723	0.00114	CcSEcCtD
Nedocromil—HSP90AA1—Metabolism—CYP2S1—psoriasis	0.000723	0.0021	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling by EGFR in Cancer—TYK2—psoriasis	0.000723	0.0021	CbGpPWpGaD
Nedocromil—Urticaria—Cyclosporine—psoriasis	0.00072	0.00114	CcSEcCtD
Nedocromil—Abdominal pain—Cyclosporine—psoriasis	0.000717	0.00113	CcSEcCtD
Nedocromil—Body temperature increased—Cyclosporine—psoriasis	0.000717	0.00113	CcSEcCtD
Nedocromil—Vomiting—Mycophenolic acid—psoriasis	0.000712	0.00113	CcSEcCtD
Nedocromil—Dyspepsia—Hydrocortisone—psoriasis	0.000709	0.00112	CcSEcCtD
Nedocromil—Rash—Mycophenolic acid—psoriasis	0.000706	0.00112	CcSEcCtD
Nedocromil—Dermatitis—Mycophenolic acid—psoriasis	0.000706	0.00111	CcSEcCtD
Nedocromil—Pain—Prednisolone—psoriasis	0.000705	0.00111	CcSEcCtD
Nedocromil—Urticaria—Mycophenolate mofetil—psoriasis	0.000702	0.00111	CcSEcCtD
Nedocromil—Headache—Mycophenolic acid—psoriasis	0.000702	0.00111	CcSEcCtD
Nedocromil—Pharyngitis—Methotrexate—psoriasis	0.0007	0.00111	CcSEcCtD
Nedocromil—Body temperature increased—Mycophenolate mofetil—psoriasis	0.000699	0.0011	CcSEcCtD
Nedocromil—Abdominal pain—Mycophenolate mofetil—psoriasis	0.000699	0.0011	CcSEcCtD
Nedocromil—CYSLTR2—Signaling Pathways—CCL20—psoriasis	0.000698	0.00203	CbGpPWpGaD
Nedocromil—Gastrointestinal disorder—Hydrocortisone—psoriasis	0.000696	0.0011	CcSEcCtD
Nedocromil—Fatigue—Hydrocortisone—psoriasis	0.000695	0.0011	CcSEcCtD
Nedocromil—Pain—Hydrocortisone—psoriasis	0.000689	0.00109	CcSEcCtD
Nedocromil—Anaphylactic shock—Betamethasone—psoriasis	0.000688	0.00109	CcSEcCtD
Nedocromil—Anaphylactic shock—Dexamethasone—psoriasis	0.000688	0.00109	CcSEcCtD
Nedocromil—Visual impairment—Methotrexate—psoriasis	0.000679	0.00107	CcSEcCtD
Nedocromil—Dyspnoea—Triamcinolone—psoriasis	0.000676	0.00107	CcSEcCtD
Nedocromil—HSP90AA1—Signaling Pathways—HCAR2—psoriasis	0.000668	0.00194	CbGpPWpGaD
Nedocromil—Hypersensitivity—Cyclosporine—psoriasis	0.000668	0.00105	CcSEcCtD
Nedocromil—Dyspepsia—Triamcinolone—psoriasis	0.000668	0.00105	CcSEcCtD
Nedocromil—HSP90AA1—Glucocorticoid receptor regulatory network—IL6—psoriasis	0.000666	0.00194	CbGpPWpGaD
Nedocromil—Nausea—Mycophenolic acid—psoriasis	0.000666	0.00105	CcSEcCtD
Nedocromil—Gastrointestinal pain—Hydrocortisone—psoriasis	0.000659	0.00104	CcSEcCtD
Nedocromil—Urticaria—Prednisolone—psoriasis	0.000655	0.00103	CcSEcCtD
Nedocromil—Fatigue—Triamcinolone—psoriasis	0.000654	0.00103	CcSEcCtD
Nedocromil—HSP90AA1—Immune System—DDX58—psoriasis	0.000654	0.0019	CbGpPWpGaD
Nedocromil—Hypersensitivity—Mycophenolate mofetil—psoriasis	0.000652	0.00103	CcSEcCtD
Nedocromil—Asthenia—Cyclosporine—psoriasis	0.00065	0.00103	CcSEcCtD
Nedocromil—Pain—Triamcinolone—psoriasis	0.000649	0.00102	CcSEcCtD
Nedocromil—Urticaria—Hydrocortisone—psoriasis	0.00064	0.00101	CcSEcCtD
Nedocromil—Body temperature increased—Hydrocortisone—psoriasis	0.000637	0.00101	CcSEcCtD
Nedocromil—Abdominal pain—Hydrocortisone—psoriasis	0.000637	0.00101	CcSEcCtD
Nedocromil—Asthenia—Mycophenolate mofetil—psoriasis	0.000634	0.001	CcSEcCtD
Nedocromil—CYSLTR2—GPCR ligand binding—CXCL8—psoriasis	0.000622	0.00181	CbGpPWpGaD
Nedocromil—Diarrhoea—Cyclosporine—psoriasis	0.00062	0.000979	CcSEcCtD
Nedocromil—CYSLTR2—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	0.000619	0.0018	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—HLA-E—psoriasis	0.000608	0.00177	CbGpPWpGaD
Nedocromil—Hypersensitivity—Prednisolone—psoriasis	0.000608	0.00096	CcSEcCtD
Nedocromil—HSP90AA1—TNF alpha Signaling Pathway—IL6—psoriasis	0.000607	0.00177	CbGpPWpGaD
Nedocromil—Dyspepsia—Dexamethasone—psoriasis	0.000606	0.000957	CcSEcCtD
Nedocromil—Dyspepsia—Betamethasone—psoriasis	0.000606	0.000957	CcSEcCtD
Nedocromil—Diarrhoea—Mycophenolate mofetil—psoriasis	0.000605	0.000955	CcSEcCtD
Nedocromil—Urticaria—Triamcinolone—psoriasis	0.000603	0.000952	CcSEcCtD
Nedocromil—Dysgeusia—Methotrexate—psoriasis	0.000601	0.000949	CcSEcCtD
Nedocromil—Body temperature increased—Triamcinolone—psoriasis	0.0006	0.000947	CcSEcCtD
Nedocromil—Dizziness—Cyclosporine—psoriasis	0.000599	0.000947	CcSEcCtD
Nedocromil—Anaphylactic shock—Prednisone—psoriasis	0.000599	0.000947	CcSEcCtD
Nedocromil—Gastrointestinal disorder—Dexamethasone—psoriasis	0.000594	0.000938	CcSEcCtD
Nedocromil—Gastrointestinal disorder—Betamethasone—psoriasis	0.000594	0.000938	CcSEcCtD
Nedocromil—Hypersensitivity—Hydrocortisone—psoriasis	0.000594	0.000937	CcSEcCtD
Nedocromil—Fatigue—Dexamethasone—psoriasis	0.000593	0.000937	CcSEcCtD
Nedocromil—Fatigue—Betamethasone—psoriasis	0.000593	0.000937	CcSEcCtD
Nedocromil—Pain—Betamethasone—psoriasis	0.000589	0.000929	CcSEcCtD
Nedocromil—Pain—Dexamethasone—psoriasis	0.000589	0.000929	CcSEcCtD
Nedocromil—Dizziness—Mycophenolate mofetil—psoriasis	0.000585	0.000923	CcSEcCtD
Nedocromil—HSP90AA1—Signaling Pathways—TAGAP—psoriasis	0.000579	0.00168	CbGpPWpGaD
Nedocromil—Asthenia—Hydrocortisone—psoriasis	0.000578	0.000913	CcSEcCtD
Nedocromil—Vomiting—Cyclosporine—psoriasis	0.000576	0.00091	CcSEcCtD
Nedocromil—Rash—Cyclosporine—psoriasis	0.000572	0.000903	CcSEcCtD
Nedocromil—Dermatitis—Cyclosporine—psoriasis	0.000571	0.000902	CcSEcCtD
Nedocromil—Headache—Cyclosporine—psoriasis	0.000568	0.000897	CcSEcCtD
Nedocromil—CYSLTR1—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	0.000566	0.00164	CbGpPWpGaD
Nedocromil—Gastrointestinal pain—Betamethasone—psoriasis	0.000563	0.000889	CcSEcCtD
Nedocromil—Gastrointestinal pain—Dexamethasone—psoriasis	0.000563	0.000889	CcSEcCtD
Nedocromil—Vomiting—Mycophenolate mofetil—psoriasis	0.000562	0.000888	CcSEcCtD
Nedocromil—Hypersensitivity—Triamcinolone—psoriasis	0.000559	0.000883	CcSEcCtD
Nedocromil—Rash—Mycophenolate mofetil—psoriasis	0.000558	0.00088	CcSEcCtD
Nedocromil—Dermatitis—Mycophenolate mofetil—psoriasis	0.000557	0.00088	CcSEcCtD
Nedocromil—Headache—Mycophenolate mofetil—psoriasis	0.000554	0.000875	CcSEcCtD
Nedocromil—Diarrhoea—Hydrocortisone—psoriasis	0.000551	0.00087	CcSEcCtD
Nedocromil—Leukopenia—Methotrexate—psoriasis	0.000549	0.000868	CcSEcCtD
Nedocromil—Urticaria—Dexamethasone—psoriasis	0.000547	0.000863	CcSEcCtD
Nedocromil—Urticaria—Betamethasone—psoriasis	0.000547	0.000863	CcSEcCtD
Nedocromil—Dizziness—Prednisolone—psoriasis	0.000545	0.000861	CcSEcCtD
Nedocromil—Asthenia—Triamcinolone—psoriasis	0.000544	0.000859	CcSEcCtD
Nedocromil—Body temperature increased—Dexamethasone—psoriasis	0.000544	0.000859	CcSEcCtD
Nedocromil—Abdominal pain—Dexamethasone—psoriasis	0.000544	0.000859	CcSEcCtD
Nedocromil—Abdominal pain—Betamethasone—psoriasis	0.000544	0.000859	CcSEcCtD
Nedocromil—Body temperature increased—Betamethasone—psoriasis	0.000544	0.000859	CcSEcCtD
Nedocromil—Nausea—Cyclosporine—psoriasis	0.000538	0.00085	CcSEcCtD
Nedocromil—HSP90AA1—VEGFA-VEGFR2 Pathway—IL6—psoriasis	0.000538	0.00156	CbGpPWpGaD
Nedocromil—Cough—Methotrexate—psoriasis	0.000536	0.000846	CcSEcCtD
Nedocromil—Dizziness—Hydrocortisone—psoriasis	0.000533	0.000841	CcSEcCtD
Nedocromil—Dyspepsia—Prednisone—psoriasis	0.000528	0.000833	CcSEcCtD
Nedocromil—Nausea—Mycophenolate mofetil—psoriasis	0.000525	0.000829	CcSEcCtD
Nedocromil—Chest pain—Methotrexate—psoriasis	0.000523	0.000825	CcSEcCtD
Nedocromil—Rash—Prednisolone—psoriasis	0.00052	0.000821	CcSEcCtD
Nedocromil—Dermatitis—Prednisolone—psoriasis	0.00052	0.000821	CcSEcCtD
Nedocromil—Fatigue—Prednisone—psoriasis	0.000517	0.000816	CcSEcCtD
Nedocromil—Headache—Prednisolone—psoriasis	0.000517	0.000816	CcSEcCtD
Nedocromil—Vomiting—Hydrocortisone—psoriasis	0.000512	0.000809	CcSEcCtD
Nedocromil—HSP90AA1—Signaling by VEGF—IL6—psoriasis	0.000508	0.00148	CbGpPWpGaD
Nedocromil—Rash—Hydrocortisone—psoriasis	0.000508	0.000802	CcSEcCtD
Nedocromil—HSP90AA1—Innate Immune System—SOCS1—psoriasis	0.000508	0.00148	CbGpPWpGaD
Nedocromil—Dermatitis—Hydrocortisone—psoriasis	0.000507	0.000801	CcSEcCtD
Nedocromil—FPR1—Signaling Pathways—SOCS1—psoriasis	0.000507	0.00147	CbGpPWpGaD
Nedocromil—Headache—Hydrocortisone—psoriasis	0.000505	0.000797	CcSEcCtD
Nedocromil—Dizziness—Triamcinolone—psoriasis	0.000502	0.000792	CcSEcCtD
Nedocromil—Anaphylactic shock—Methotrexate—psoriasis	0.000501	0.000791	CcSEcCtD
Nedocromil—HSP90AA1—Immune System—ITGAL—psoriasis	0.000496	0.00144	CbGpPWpGaD
Nedocromil—Asthenia—Dexamethasone—psoriasis	0.000494	0.00078	CcSEcCtD
Nedocromil—Asthenia—Betamethasone—psoriasis	0.000494	0.00078	CcSEcCtD
Nedocromil—Gastrointestinal pain—Prednisone—psoriasis	0.00049	0.000774	CcSEcCtD
Nedocromil—Nausea—Prednisolone—psoriasis	0.00049	0.000774	CcSEcCtD
Nedocromil—PTGDR—Signaling Pathways—SOCS1—psoriasis	0.00049	0.00142	CbGpPWpGaD
Nedocromil—HSP90AA1—Cell Cycle, Mitotic—PCNA—psoriasis	0.000487	0.00142	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—CCL20—psoriasis	0.000484	0.00141	CbGpPWpGaD
Nedocromil—FPR1—Signaling by GPCR—TYK2—psoriasis	0.000483	0.0014	CbGpPWpGaD
Nedocromil—Vomiting—Triamcinolone—psoriasis	0.000482	0.000762	CcSEcCtD
Nedocromil—Nausea—Hydrocortisone—psoriasis	0.000479	0.000756	CcSEcCtD
Nedocromil—Rash—Triamcinolone—psoriasis	0.000478	0.000755	CcSEcCtD
Nedocromil—Dermatitis—Triamcinolone—psoriasis	0.000478	0.000755	CcSEcCtD
Nedocromil—Urticaria—Prednisone—psoriasis	0.000476	0.000752	CcSEcCtD
Nedocromil—Headache—Triamcinolone—psoriasis	0.000475	0.00075	CcSEcCtD
Nedocromil—Abdominal pain—Prednisone—psoriasis	0.000474	0.000748	CcSEcCtD
Nedocromil—Body temperature increased—Prednisone—psoriasis	0.000474	0.000748	CcSEcCtD
Nedocromil—Diarrhoea—Dexamethasone—psoriasis	0.000471	0.000744	CcSEcCtD
Nedocromil—Diarrhoea—Betamethasone—psoriasis	0.000471	0.000744	CcSEcCtD
Nedocromil—PTGDR—Signaling by GPCR—TYK2—psoriasis	0.000467	0.00136	CbGpPWpGaD
Nedocromil—HSP90AA1—Cellular responses to stress—CXCL8—psoriasis	0.000465	0.00135	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—REL—psoriasis	0.000463	0.00135	CbGpPWpGaD
Nedocromil—FPR1—GPCR downstream signaling—CXCL8—psoriasis	0.000463	0.00135	CbGpPWpGaD
Nedocromil—Dizziness—Betamethasone—psoriasis	0.000455	0.000719	CcSEcCtD
Nedocromil—Dizziness—Dexamethasone—psoriasis	0.000455	0.000719	CcSEcCtD
Nedocromil—HSP90AA1—Axon guidance—TYK2—psoriasis	0.000454	0.00132	CbGpPWpGaD
Nedocromil—Nausea—Triamcinolone—psoriasis	0.000451	0.000712	CcSEcCtD
Nedocromil—HSP90AA1—Immune System—IFIH1—psoriasis	0.00045	0.00131	CbGpPWpGaD
Nedocromil—PTGDR—GPCR downstream signaling—CXCL8—psoriasis	0.000448	0.0013	CbGpPWpGaD
Nedocromil—Dyspnoea—Methotrexate—psoriasis	0.000447	0.000705	CcSEcCtD
Nedocromil—Hypersensitivity—Prednisone—psoriasis	0.000442	0.000697	CcSEcCtD
Nedocromil—Dyspepsia—Methotrexate—psoriasis	0.000441	0.000696	CcSEcCtD
Nedocromil—Vomiting—Dexamethasone—psoriasis	0.000438	0.000691	CcSEcCtD
Nedocromil—Vomiting—Betamethasone—psoriasis	0.000438	0.000691	CcSEcCtD
Nedocromil—HSP90AA1—Cell Cycle—PCNA—psoriasis	0.000436	0.00127	CbGpPWpGaD
Nedocromil—Rash—Betamethasone—psoriasis	0.000434	0.000685	CcSEcCtD
Nedocromil—Rash—Dexamethasone—psoriasis	0.000434	0.000685	CcSEcCtD
Nedocromil—Dermatitis—Dexamethasone—psoriasis	0.000434	0.000685	CcSEcCtD
Nedocromil—Dermatitis—Betamethasone—psoriasis	0.000434	0.000685	CcSEcCtD
Nedocromil—HSP90AA1—Innate Immune System—HLA-B—psoriasis	0.000433	0.00126	CbGpPWpGaD
Nedocromil—HSP90AA1—Cellular responses to stress—JUN—psoriasis	0.000433	0.00126	CbGpPWpGaD
Nedocromil—Gastrointestinal disorder—Methotrexate—psoriasis	0.000432	0.000683	CcSEcCtD
Nedocromil—Fatigue—Methotrexate—psoriasis	0.000432	0.000682	CcSEcCtD
Nedocromil—Headache—Betamethasone—psoriasis	0.000431	0.000681	CcSEcCtD
Nedocromil—Headache—Dexamethasone—psoriasis	0.000431	0.000681	CcSEcCtD
Nedocromil—CYSLTR1—GPCR ligand binding—CXCL8—psoriasis	0.000431	0.00125	CbGpPWpGaD
Nedocromil—Asthenia—Prednisone—psoriasis	0.00043	0.000679	CcSEcCtD
Nedocromil—CYSLTR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	0.000429	0.00125	CbGpPWpGaD
Nedocromil—Pain—Methotrexate—psoriasis	0.000428	0.000676	CcSEcCtD
Nedocromil—HSP90AA1—Immune System—HLA-C—psoriasis	0.000427	0.00124	CbGpPWpGaD
Nedocromil—HSP90AA1—Developmental Biology—LEP—psoriasis	0.000424	0.00123	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—TNFAIP3—psoriasis	0.000421	0.00122	CbGpPWpGaD
Nedocromil—FPR1—Signaling by GPCR—CXCL8—psoriasis	0.000421	0.00122	CbGpPWpGaD
Nedocromil—HSP90AA1—Cellular responses to stress—NFKB1—psoriasis	0.000416	0.00121	CbGpPWpGaD
Nedocromil—Diarrhoea—Prednisone—psoriasis	0.00041	0.000648	CcSEcCtD
Nedocromil—Gastrointestinal pain—Methotrexate—psoriasis	0.00041	0.000647	CcSEcCtD
Nedocromil—Nausea—Betamethasone—psoriasis	0.000409	0.000646	CcSEcCtD
Nedocromil—Nausea—Dexamethasone—psoriasis	0.000409	0.000646	CcSEcCtD
Nedocromil—PTGDR—Signaling by GPCR—CXCL8—psoriasis	0.000406	0.00118	CbGpPWpGaD
Nedocromil—Urticaria—Methotrexate—psoriasis	0.000398	0.000628	CcSEcCtD
Nedocromil—Dizziness—Prednisone—psoriasis	0.000396	0.000626	CcSEcCtD
Nedocromil—Body temperature increased—Methotrexate—psoriasis	0.000396	0.000625	CcSEcCtD
Nedocromil—Abdominal pain—Methotrexate—psoriasis	0.000396	0.000625	CcSEcCtD
Nedocromil—HSP90AA1—Signaling by ERBB2—IL6—psoriasis	0.000384	0.00112	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—SOCS1—psoriasis	0.000384	0.00112	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—CRP—psoriasis	0.000383	0.00111	CbGpPWpGaD
Nedocromil—Vomiting—Prednisone—psoriasis	0.000381	0.000602	CcSEcCtD
Nedocromil—Rash—Prednisone—psoriasis	0.000378	0.000597	CcSEcCtD
Nedocromil—HSP90AA1—Cellular responses to stress—VEGFA—psoriasis	0.000378	0.0011	CbGpPWpGaD
Nedocromil—Dermatitis—Prednisone—psoriasis	0.000378	0.000596	CcSEcCtD
Nedocromil—Headache—Prednisone—psoriasis	0.000376	0.000593	CcSEcCtD
Nedocromil—HSP90AA1—Cellular responses to stress—STAT3—psoriasis	0.000374	0.00109	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—LEP—psoriasis	0.000374	0.00109	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—APOE—psoriasis	0.000374	0.00109	CbGpPWpGaD
Nedocromil—HSP90AA1—Developmental Biology—PPARG—psoriasis	0.000369	0.00107	CbGpPWpGaD
Nedocromil—Hypersensitivity—Methotrexate—psoriasis	0.000369	0.000583	CcSEcCtD
Nedocromil—CYSLTR2—Signaling by GPCR—TYK2—psoriasis	0.000366	0.00106	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—APOE—psoriasis	0.000361	0.00105	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—LEP—psoriasis	0.000361	0.00105	CbGpPWpGaD
Nedocromil—Asthenia—Methotrexate—psoriasis	0.000359	0.000568	CcSEcCtD
Nedocromil—Nausea—Prednisone—psoriasis	0.000356	0.000562	CcSEcCtD
Nedocromil—HSP90AA1—Immune System—HLA-E—psoriasis	0.000354	0.00103	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling by EGFR in Cancer—IL6—psoriasis	0.000354	0.00103	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—CARM1—psoriasis	0.000353	0.00103	CbGpPWpGaD
Nedocromil—CYSLTR2—GPCR downstream signaling—CXCL8—psoriasis	0.000351	0.00102	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—NFKBIA—psoriasis	0.000349	0.00101	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—NFKBIA—psoriasis	0.000349	0.00101	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—CCL20—psoriasis	0.000347	0.00101	CbGpPWpGaD
Nedocromil—Diarrhoea—Methotrexate—psoriasis	0.000343	0.000541	CcSEcCtD
Nedocromil—PTGDR—Signaling Pathways—NFKBIA—psoriasis	0.000337	0.000979	CbGpPWpGaD
Nedocromil—Dizziness—Methotrexate—psoriasis	0.000331	0.000523	CcSEcCtD
Nedocromil—HSP90AA1—Developmental Biology—TYK2—psoriasis	0.000324	0.000941	CbGpPWpGaD
Nedocromil—HSP90AA1—Axon guidance—VEGFA—psoriasis	0.000321	0.000932	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling by GPCR—CXCL8—psoriasis	0.000319	0.000927	CbGpPWpGaD
Nedocromil—Vomiting—Methotrexate—psoriasis	0.000319	0.000503	CcSEcCtD
Nedocromil—Rash—Methotrexate—psoriasis	0.000316	0.000499	CcSEcCtD
Nedocromil—Dermatitis—Methotrexate—psoriasis	0.000316	0.000498	CcSEcCtD
Nedocromil—Headache—Methotrexate—psoriasis	0.000314	0.000496	CcSEcCtD
Nedocromil—Nausea—Methotrexate—psoriasis	0.000298	0.00047	CcSEcCtD
Nedocromil—HSP90AA1—Immune System—SOCS1—psoriasis	0.000296	0.000859	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—TYK2—psoriasis	0.000286	0.000831	CbGpPWpGaD
Nedocromil—HSP90AA1—Cellular responses to stress—TP53—psoriasis	0.000286	0.00083	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—TYK2—psoriasis	0.000286	0.00083	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—LEP—psoriasis	0.000284	0.000824	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—APOE—psoriasis	0.000284	0.000824	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—TYK2—psoriasis	0.000276	0.000802	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—SOCS1—psoriasis	0.000266	0.000774	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—NFKBIA—psoriasis	0.000264	0.000768	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—CD8A—psoriasis	0.000262	0.000762	CbGpPWpGaD
Nedocromil—HSP90AA1—Cellular responses to stress—IL6—psoriasis	0.000261	0.00076	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—CD4—psoriasis	0.000259	0.000752	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—TYK2—psoriasis	0.000254	0.000738	CbGpPWpGaD
Nedocromil—HSP90AA1—Developmental Biology—NFKB1—psoriasis	0.000252	0.000733	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—HLA-B—psoriasis	0.000252	0.000733	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—CXCL8—psoriasis	0.000249	0.000723	CbGpPWpGaD
Nedocromil—CYSLTR1—GPCR downstream signaling—CXCL8—psoriasis	0.000243	0.000708	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—CXCL8—psoriasis	0.00024	0.000698	CbGpPWpGaD
Nedocromil—FPR1—Signaling by GPCR—IL6—psoriasis	0.000236	0.000687	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—HLA-A—psoriasis	0.000234	0.000679	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—JUN—psoriasis	0.000231	0.000673	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—JUN—psoriasis	0.000231	0.000672	CbGpPWpGaD
Nedocromil—HSP90AA1—Developmental Biology—VEGFA—psoriasis	0.000229	0.000665	CbGpPWpGaD
Nedocromil—PTGDR—Signaling by GPCR—IL6—psoriasis	0.000228	0.000664	CbGpPWpGaD
Nedocromil—HSP90AA1—Developmental Biology—STAT3—psoriasis	0.000227	0.000659	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—JUN—psoriasis	0.000223	0.000649	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—CRP—psoriasis	0.000223	0.000648	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—NFKB1—psoriasis	0.000223	0.000648	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—NFKB1—psoriasis	0.000222	0.000647	CbGpPWpGaD
Nedocromil—HSP90AA1—Axon guidance—IL6—psoriasis	0.000222	0.000645	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—CXCL8—psoriasis	0.000221	0.000643	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—CAT—psoriasis	0.000217	0.000631	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—TYK2—psoriasis	0.000216	0.000629	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—HLA-A—psoriasis	0.000216	0.000627	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—NFKB1—psoriasis	0.000215	0.000625	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—HLA-DRB1—psoriasis	0.000214	0.000621	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—ICAM1—psoriasis	0.000205	0.000596	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—NFKBIA—psoriasis	0.000203	0.000591	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—VEGFA—psoriasis	0.000202	0.000587	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—APOE—psoriasis	0.000201	0.000586	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—STAT3—psoriasis	0.0002	0.000581	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—APOE—psoriasis	0.000197	0.000571	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—LEP—psoriasis	0.000197	0.000571	CbGpPWpGaD
Nedocromil—HSP90AA1—Developmental Biology—TNF—psoriasis	0.000196	0.00057	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—VEGFA—psoriasis	0.000195	0.000567	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—STAT3—psoriasis	0.000193	0.000561	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—SOCS1—psoriasis	0.000191	0.000556	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—CXCL8—psoriasis	0.000188	0.000548	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—NOS2—psoriasis	0.000188	0.000546	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—NFKBIA—psoriasis	0.000183	0.000532	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling by GPCR—IL6—psoriasis	0.000179	0.000521	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—JUN—psoriasis	0.000175	0.000509	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—APOE—psoriasis	0.000169	0.00049	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—NFKB1—psoriasis	0.000169	0.00049	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—TYK2—psoriasis	0.000167	0.000484	CbGpPWpGaD
Nedocromil—HSP90AA1—Cell Cycle—TP53—psoriasis	0.00016	0.000465	CbGpPWpGaD
Nedocromil—HSP90AA1—Developmental Biology—IL6—psoriasis	0.000158	0.00046	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—IFNG—psoriasis	0.000156	0.000453	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—TYK2—psoriasis	0.000154	0.000447	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—VEGFA—psoriasis	0.000153	0.000445	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—TP53—psoriasis	0.000153	0.000443	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—STAT3—psoriasis	0.000152	0.00044	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—CD4—psoriasis	0.000151	0.000438	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—TYK2—psoriasis	0.00015	0.000436	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—TP53—psoriasis	0.000147	0.000428	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—PPARG—psoriasis	0.000147	0.000427	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—LEP—psoriasis	0.000141	0.00041	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—APOE—psoriasis	0.000141	0.00041	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—IL6—psoriasis	0.00014	0.000406	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—IL6—psoriasis	0.00014	0.000406	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—CD4—psoriasis	0.000139	0.000404	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—IL6—psoriasis	0.000135	0.000392	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—JUN—psoriasis	0.000135	0.000392	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—NFKBIA—psoriasis	0.000131	0.000382	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—CXCL8—psoriasis	0.000131	0.00038	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—NFKB1—psoriasis	0.00013	0.000377	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—IL6—psoriasis	0.000124	0.000361	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—JUN—psoriasis	0.000121	0.000353	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—NFKB1—psoriasis	0.000117	0.00034	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—STAT3—psoriasis	0.000117	0.000339	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—TP53—psoriasis	0.000116	0.000336	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—TYK2—psoriasis	0.000108	0.000313	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—STAT3—psoriasis	0.000108	0.000313	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—VEGFA—psoriasis	0.000106	0.000308	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—IL6—psoriasis	0.000106	0.000308	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—STAT3—psoriasis	0.000105	0.000305	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—CXCL8—psoriasis	9.37e-05	0.000272	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—JUN—psoriasis	8.72e-05	0.000253	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—NFKB1—psoriasis	8.39e-05	0.000244	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—IL6—psoriasis	8.14e-05	0.000237	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—TP53—psoriasis	8.01e-05	0.000233	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—VEGFA—psoriasis	7.61e-05	0.000221	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—STAT3—psoriasis	7.54e-05	0.000219	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—IL6—psoriasis	7.52e-05	0.000219	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—IL6—psoriasis	7.34e-05	0.000213	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—TP53—psoriasis	5.75e-05	0.000167	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—IL6—psoriasis	5.27e-05	0.000153	CbGpPWpGaD
